Bell's palsy tied to quadrivalent meningococcal vaccine

Bell's palsy tied to quadrivalent meningococcal vaccine

(HealthDay)—Bell's palsy is the only prespecified adverse event associated with the MenACWY-CRM quadrivalent meningococcal conjugate vaccine, according to a study published online Dec. 26 in Pediatrics.

Hung-Fu Tseng, Ph.D., from the Southern California Permanente Medical Group in Pasadena, and colleagues evaluated data from 48,899 individuals, aged 11 to 21 years, receiving MenACWY-CRM, a quadrivalent , between Sept. 30, 2011, and June 30, 2013. Electronic health records were used to identify 26 prespecified events of interest (EOIs) for up to one year after vaccination.

The researchers found that no cases were observed in the risk window for 14 of 26 EOIs. The relative incidence (RI) for Bell's palsy was statistically significant at 2.9 (95 percent confidence interval, 1.1 to 7.5). An increased risk for Bell's palsy in subjects receiving concomitant vaccines (RI, 5.0; 95 percent confidence interval, 1.4 to 17.8) was seen in stratified analyses, but no increased risk was seen for those without concomitant (RI, 1.1; 95 percent confidence interval, 0.2 to 5.5).

"The association needs further investigation as it could be due to chance, concomitant vaccination, or underlying medical history predisposing to Bell's palsy," the authors write.

Several authors disclosed financial ties to Novartis Vaccines and Diagnostics (now part of GlaxoSmithKline Vaccines), which funded the study.

Explore further

No increase in febrile seizures with 2010-2011 TIV or PCV13

More information: Full Text
Journal information: Pediatrics

Copyright © 2016 HealthDay. All rights reserved.

Citation: Bell's palsy tied to quadrivalent meningococcal vaccine (2016, December 28) retrieved 30 September 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors